Spark Therapeutics Inc (NASDAQ:ONCE) has been given a consensus rating of “Buy” by the twenty-two research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $76.03.
A number of brokerages recently issued reports on ONCE. Cantor Fitzgerald decreased their price objective on shares of Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating for the company in a report on Friday, October 13th. Cowen restated a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Raymond James Financial reaffirmed a “buy” rating and issued a $75.00 price target on shares of Spark Therapeutics in a research note on Thursday, December 7th. Barclays lifted their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the company an “overweight” rating in a research note on Friday, October 13th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of Spark Therapeutics in a research note on Friday, October 13th.
In other news, insider Daniel Faga sold 6,000 shares of the business’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $79.95, for a total value of $479,700.00. Following the sale, the insider now owns 6,000 shares of the company’s stock, valued at $479,700. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Barge Joseph La sold 5,500 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the completion of the sale, the insider now directly owns 8,146 shares in the company, valued at approximately $581,950.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,309 shares of company stock worth $4,621,085. Insiders own 7.30% of the company’s stock.
Shares of Spark Therapeutics (NASDAQ ONCE) traded down $3.92 during midday trading on Friday, reaching $51.84. 1,785,400 shares of the company were exchanged, compared to its average volume of 1,199,500. The firm has a market capitalization of $1,840.00 and a PE ratio of -7.20. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.07) EPS. equities research analysts predict that Spark Therapeutics will post -7.58 earnings per share for the current fiscal year.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.